Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy

Hepatology Research

Volumn 45, Issue 10, 2015, Pages E115-E121

  Itakura, Jun ^a   Kurosaki, Masayuki ^a   Takada, Hitomi ^a   Nakakuki, Natsuko ^a   Matsuda, Syuya ^a   Gondou, Kouichi ^a   Asano, Yu ^a   Hattori, Nobuhiro ^a   Itakura, Yoshie ^a   Tamaki, Nobuharu ^a   Yasui, Yutaka ^a   Suzuki, Shoko ^a   Hosokawa, Takanori ^a   Tsuchiya, Kaoru ^a   Nakanishi, Hiroyuki ^a   Takahashi, Yuka ^a   Maekawa, Syinya ^b   Enomoto, Nobuyuki ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Direct acting antivirals; Hepatitis C virus; Interferon based therapy; Interleukin 28B genotype; Resistance associated variants

Indexed keywords

INTERLEUKIN 28B; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C VIRUS SUBTYPE 1B; HEPATITIS C VIRUS SUBTYPE 1B (STRAIN Q80L); HEPATITIS C VIRUS SUBTYPE 1B (STRAIN S122); HEPATITIS C VIRUS SUBTYPE 1B (STRAIN Y93H); HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS GENOME;

EID: 84939174987     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12474     Document Type: Article

References (36)

1. Aghemo A, Francesco DR. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58: 428-438.
2. Chae HB, Park SM, Youn SJ. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. Scientific World J 2013; 2013: 704912. doi: 10.1155/2013/704912
3. Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol 2013; 19: 8963-8973.
4. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
5. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
6. Salvatierra K, Fareleski S, Forcada A, López-Labrador FX. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World J Virol 2013; 2: 6-15.
7. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-1751.
8. Kuntzen T, Timm J, Berical A et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-1778.
9. Bartels DJ, Sullivan JC, Zhang EZ et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87: 1544-1553.
10. Robinson M, Tian Y, Delaney WE 4th, Greenstein AE. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc Natl Acad Sci U S A 2011; 108: 10290-10295.
11. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
12. Akuta N, Suzuki F, Sezaki H et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90.
13. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-9.
14. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011; 55: 692-701.
15. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-1876.
16. Izumi N. Efficacy of daclatasvir in hepatitis C virus. Expert Rev Anti Infect Ther 2014; 12: 1025-31.
17. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146:1669-1679.
18. Recommendations for Testing, Managing, and Treating Hepatitis C 2014 by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org
19. Pawlotzky JM et al. EASL Recommendations on Treatment of Hepatitis C 2014. Available at: http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014. Accessed January 11, 2015.
20. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800-807.
21. Susser S, Welsch C, Wang Y et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-1718.
22. Lenz O, Verbinnen T, Lin TI et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878-1887.
23. Summa V, Ludmerer SW, McCauley JA et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56: 4161-4167.
24. Barnard RJ, McHale CM, Newhard W et al. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology 2013; 443: 278-284.
25. McPhee F, Hernandez D, Yu F et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013; 58: 902-911.
26. Fridell RA, Wang C, Sun JH et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-1935.
27. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20: 2902-2912.
28. Karino Y, Toyota J, Ikeda K et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-654.
29. Miura M, Maekawa S, Sato M et al. Deep Sequencing Analysis of Variants Resistant to the NS5A Inhibitor Daclatasvir in Patients with Genotype 1b Hepatitis C Virus Infection. Hepatol Res 2014; 44: E360-7.
30. Izumi N, Yokosuka O, Kawada N et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther 2014; 19: 501-10.
31. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
32. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
33. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
34. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: Do we need resistance testing? Antiviral Res 2014; 105: 64-71.
35. Barnard RJ, Howe JA, Ogert RA et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013; 444: 329-336.
36. Sullivan JC, De Meyer S, Bartels DJ et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57: 221-229.